Integra LifeSciences Holding Corporation
IART
is scheduled to report first-quarter 2021 results on Apr 28, before the opening bell.
In the last reported quarter, the company’s earnings of $2.45 surpassed the Zacks Consensus Estimate by 3.8%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on three occasions and missed on one, with the average surprise being 86.6%.
Let’s see how things have shaped up prior to this announcement.
Factors to Note
Just like the last reported quarter, operations in both the business segments might have remained challenging for Integra through the first quarter.
CSS
Integra’s Codman Specialty Surgical (CSS) segment’s results are expected to reflect potential growth in first-quarter 2021 on continued robust demand for market-leading products including DuraGen, antimicrobial catheters and service programmable valves. In the fourth quarter, robust sales of these products compensated the company’s pandemic-induced operating loss. With the health situation remaining more-or-less unchanged, this trend is expected to have been repeated in the to-be-reported quarter.
Furthermore, Integra registered revenue growth in Japan banking on strong customer adoption of the neurosurgery portfolio. This is expected to have once again contributed to the company’s top line. In China too, the distribution deal with local Chinese partner has been gaining larger market access. This is expected to have contributed to the CSS growth rate.
Integra LifeSciences Holdings Corporation Price and EPS Surprise
Integra LifeSciences Holdings Corporation price-eps-surprise
|
Integra LifeSciences Holdings Corporation Quote
We expect the addition of ACell and expansion of the tissue technology platform to have driven first-quarter 2021 growth.
OTT
In January 2021, the company divested the non-core extremity orthopedic business within the Orthopedics and Tissue Technologies arm to focus more on the profitable part of the arm. During fourth-quarter earnings call, it noted that this discontinued business will have a negative impact on 2021 growth. We believe, this should reflect on first-quarter 2021 results as well.
However, as the pandemic took a graver form, demand for the Integra’s surgical procedures declined significantly, resulting in dramatic sales decline. During the company’s February update, the company noted that the recovery rate of surgical procedures and capital equipment sales should remain variable as the course of the pandemic remains uncertain. The slower recovery rate is likely to have impeded Integra’s first-quarter growth.
Estimate Picture
For first-quarter 2021, the Zacks Consensus Estimate for total revenues of $349.9 million implies a decline of 1.3% from the prior-year reported figure.
The consensus estimate for earnings per share is pegged at 56 cents, implying an improvement of 16.7% from the prior-year reported figure.
What Our Model Suggests
Our proven model does not conclusively predict an earnings beat for Integra this time around. The combination of a positive
Earnings ESP
and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) increases the chances of an earnings beat.
Earnings ESP:
Integra has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our
Earnings ESP Filter.
Zacks Rank:
The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.
Elanco Animal Health Incorporated
ELAN
currently has a Zacks Rank #1 and an Earnings ESP of +1.90%. You can see
the complete list of today’s Zacks #1 Rank stocks here
.
HCA Healthcare, Inc.
HCA
has an Earnings ESP of +8.91% and a Zacks Rank of 2, at present.
Avenue Therapeutics, Inc.
ATXI
has an Earnings ESP of +16.67% and a Zacks Rank of 2, at present.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report